Join Heather Mambretti, PA-C, a rheumatology expert in Houston, Texas, and RhAPP member, as she explores the critical role of CD64-positive binding in IL-23 inhibition and its impact on autoimmune disease treatment.CD64, a high-affinity receptor expressed on myeloid lineage immune cells, plays a pivotal role in inflammatory signaling. IL-23, a key driver of inflammation in psoriatic arthritis, psoriasis, and inflammatory bowel disease, promotes pathogenic TH17 cell differentiation, contributing to chronic inflammation. Guselkumab (Tremfya) uniquely leverages a dual-binding mechanism, targeting both IL-23 and CD64-positive cells to enhance specificity and therapeutic efficacy.Insights from the DISCOVER-1 and DISCOVER-2 clinical trials highlight the benefits of IL-23 inhibition in psoriatic disease, demonstrating improved patient outcomes, reduced systemic inflammation, and minimized off-target effects.For more expert discussions on the latest advancements in rheumatology, visit RhAPP.org or explore the RhAPP ACE App.

Ver todos los episodios